La cadena de opciones muestra datos clave de las opciones de acciones de Femto Technologies a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Femto Technologies..

Femto Technologies (NASDAQ:FMTO) Bolsa, Cadena de Opciones

Femto Technologies

Femto Technologies Inc is an integrated software company. It owns and markets Benefit CRM, a proprietary customer relationship management CRM software product enabling small and medium sized businesses to optimize their day to day business activities such as sales management, personnel management, marketing, call center activities, and asset management.

Femto Technologies Inc

Earnings

Earnings Beats

News

JAZZ

Jazz Pharmaceuticals Q4 2024 Adj. EPS $6.60 Beats $5.81 Estimate, Sales $1.088B Beat $1.060B Estimate

Lucid Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.27) by 18.52 percent. This is a 24.14 percent increase over losses of $(0.29) per share from the same period last year. The company reported quarterly sales of $234.500 million which beat the analyst consensus estimate of $214.215 million by 9.47 percent. This is a 49.22 percent increase over sales of $157.151 million the same period last year.

LCID

Lucid Gr Q4 2024 GAAP EPS $(0.22) Beats $(0.27) Estimate, Sales $234.500M Beat $214.215M Estimate

ExlService Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXLS#NASDAQ">EXLS</a>) reported quarterly earnings of $0.44 per share which beat the analyst consensus estimate of $0.41 by 7.32 percent. This is a 25.71 percent increase over earnings of $0.35 per share from the same period last year. The company reported quarterly sales of $481.400 million which beat the analyst consensus estimate of $475.734 million by 1.19 percent. This is a 16.26 percent increase over sales of $414.058 million the same period last year.

EXLS

ExlService Holdings Q4 2024 Adj. EPS $0.44 Beats $0.41 Estimate, Sales $481.400M Beat $475.734M Estimate

Supernus Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUPN#NASDAQ">SUPN</a>) sees FY2025 sales of $600.000 million-$630.000 million vs $622.18 million analyst estimate.

Guidance

SUPN

Supernus Pharmaceuticals Sees FY2025 Sales $600.000M-$630.000M vs $622.18M Est

WIIM

FSLR

First Solar shares are trading lower following a Q4 earnings miss.

AXON

Axon Enterprises shares are trading higher after the company reported better-than-expected Q4 financial results and issued FY24 revenue guidance with its midpoint above estimates.

Supernus Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUPN#NASDAQ">SUPN</a>) reported quarterly earnings of $0.27 per share which missed the analyst consensus estimate of $0.52 by 48.08 percent. This is a 30.77 percent decrease over earnings of $0.39 per share from the same period last year. The company reported quarterly sales of $174.16 million which beat the analyst consensus estimate of $155.25 million by 12.18 percent. This is a 5.99 percent increase over sales of $164.31 million the same period last year.

Earnings Misses

Supernus Pharmaceuticals Q4 EPS $0.27 Misses $0.52 Estimate, Sales $174.16M Beat $155.25M Estimate

Solventum Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOLV#NYSE">SOLV</a>) shares are trading higher Tuesday after the company announced it will sell its purification and filtration business to Thermo Fisher for<a href="https://www.benzinga.com/25/02/43940332/thermo-fisher-bets-big-on-bioproduction-with-solventums-unit-deal-worth-41-billion"> $4.1 billion in cash. </a>
What To Know: The deal, expected to close by the end of 2025 pending regulatory approvals, will provide Solventum with approximately $3.4 billion in net proceeds, which will primarily be used to pay down debt. 
CEO Bryan Hanson stated this sale is a key part of the company's broader transformation strategy, allowing it to sharpen its focus on core growth areas while strengthening its balance sheet and reducing leverage.
&#8220;The sale of the Purification &amp; Filtration business is part of phase three of our transformation plan and follows a thorough analysis of the value and strategic alignment of our businesses,&#8221; said Hanson. 
The purification and filtration business, which supplies filters and membranes for biopharmaceuticals, medical technology, microelectronics and food and beverage production, will transition to Thermo Fisher, which is expected to invest in its continued growth. 
Solventum will discuss the transaction further during its fourth-quarter and full-year 2024 earnings call on Feb. 27, followed by an Investor Day in New York City on March 20, where it will outline its long-term strategy and progress as an independent public company.
SOLV Price Action: Solventum shares were up 9.54% at $83.56 at the time of publication Tuesday, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent022525&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="1024" height="528" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/25152846/Screenshot-2025-02-25-at-15.28.10-1024x528.png" alt="" class="wp-image-798333" style="width:477px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/25152846/Screenshot-2025-02-25-at-15.28.10-1024x528.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/25152846/Screenshot-2025-02-25-at-15.28.10-300x155.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/25152846/Screenshot-2025-02-25-at-15.28.10-768x396.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/25152846/Screenshot-2025-02-25-at-15.28.10.png 1525w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/02/43951080/bitcoin-plunges-as-consumer-confidence-falls-whats-driving-markets-tuesday">Bitcoin Plunges As Consumer Confidence Falls: What&#8217;s Driving Markets Tuesday?</a></li>
</ul>
Image Created Via Midjourney.

Movers

SOLV

Solventum Shares Are Up Today: What's Going On?

Matson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MATX#NYSE">MATX</a>) reported quarterly earnings of $3.80 per share which beat the analyst consensus estimate of $3.34 by 13.77 percent. The company reported quarterly sales of $890.30 million which beat the analyst consensus estimate of $851.78 million by 4.52 percent. This is a 12.85 percent increase over sales of $788.90 million the same period last year.

MATX

Matson Q4 2024 Adj EPS $3.80 Beats $3.34 Estimate, Sales $890.30M Beat $851.78M Estimate

Revolve Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RVLV#NYSE">RVLV</a>) reported quarterly earnings of $0.17 per share which beat the analyst consensus estimate of $0.10 by 70 percent. The company reported quarterly sales of $293.728 million which beat the analyst consensus estimate of $283.495 million by 3.61 percent. This is a 13.95 percent increase over sales of $257.778 million the same period last year.

RVLV

Revolve Gr Q4 2024 Adj. EPS $0.17 Beats $0.10 Estimate, Sales $293.728M Beat $283.495M Estimate

First Solar Sees 2025 Net Sales $5.3B-$5.8B vs $5.519B Est., EPS $17-$20

Axon Enterprise Sees FY25 Revenue $2.55B-$2.65B Vs $2.554B Est.

Keysight Techs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEYS#NYSE">KEYS</a>) reported quarterly earnings of $1.82 per share which beat the analyst consensus estimate of $1.69 by 7.69 percent. This is a 11.66 percent increase over earnings of $1.63 per share from the same period last year. The company reported quarterly sales of $1.30 billion which beat the analyst consensus estimate of $1.28 billion by 1.88 percent. This is a 3.26 percent increase over sales of $1.26 billion the same period last year.

KEYS

Keysight Techs Q1 2025 Adj EPS $1.82 Beats $1.69 Estimate, Sales $1.30B Beat $1.28B Estimate

Enveric Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVB#NASDAQ">ENVB</a>) has secured its first U.S. patent for the EVM401 Series, a novel collection of non-hallucinogenic, mescaline-derived compounds. These compounds are designed to address addiction, <a href="https://www.benzinga.com/topic/adhd">ADHD anxiety, and other </a>neuropsychiatric disorders, potentially offering new therapeutic avenues for patients who have limited options.
<h2 class="wp-block-heading">What Happened</h2>
Issued on January 14, 2025, the patent titled "Cl-Substituted Isopropylamine Fused Heterocyclic Mescaline Derivatives" covers compounds that uniquely modulate critical brain receptors associated with mental health conditions. Specifically, these molecules target the alpha-2A adrenergic receptor (ADRA2A), the serotonin 5-HT2C receptor and the dopamine transporter (DAT) &#8211; all of which play pivotal roles in neurological functions and therapeutic potential.
Speaking exclusively to <a href="https://www.benzinga.com/cannabis">Benzinga</a>, Dr. Joseph Tucker, CEO of Enveric Biosciences, said, "With the issuance of this patent, we are not only protecting our innovations but also paving the way for the next generation of neuropsychiatric treatments that move beyond traditional approaches."
Also Read: <a href="https://www.benzinga.com/general/health-care/25/02/43666635/zyn-changed-nicotine-forever-are-cannabis-pouches-the-next-big-thing">Zyn Changed Nicotine Forever &#8211; Are Cannabis Pouches The Next Big Thing?</a>
"Our strategic focus remains on advancing EB-003 toward clinical trials, but the EVM401 Series reflects our broader vision—building a robust portfolio of differentiated, next-generation therapeutics," he continued.
<h2 class="wp-block-heading">Why It Matters</h2>
By securing this patent, Enveric strengthens its position in the rapidly growing field of non-hallucinogenic psychedelic medicine, a sector that has seen increasing interest as investors and researchers seek alternatives to traditional psychiatric treatments. Unlike conventional psychedelics that induce hallucinatory experiences, the EVM401 Series aims to harness the therapeutic benefits of mescaline-derived compounds while avoiding psychoactive effects, making them more accessible for patients and easier to integrate into medical practice.
"This patent is just the beginning," Dr. Tucker told Benzinga. "As we continue to refine and develop the EVM401 Series, we remain committed to delivering safe, effective, and scalable solutions for patients who need them most."
<h2 class="wp-block-heading">What&#8217;s Next</h2>
The company remains focused on advancing its lead drug candidate, EB-003, toward regulatory approval, while simultaneously exploring opportunities to expand its therapeutic pipeline. "By broadening our pipeline with non-hallucinogenic compounds like those in the EVM401 Series, we are positioning Enveric at the forefront of the next wave of neuropsychiatric innovation," Dr. Tucker said.
With the mental health and addiction crisis continuing to rise globally, Enveric's latest patent signals an important step forward in the development of alternative therapies. The company's strategic expansion into non-hallucinogenic psychedelics could open the door for new treatment paradigms that address some of the most challenging psychiatric conditions.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/01/43278893/how-ozempic-and-legal-weed-are-changing-what-america-eats">How Ozempic And Legal Weed Are Changing What America Eats</a></li>
</ul>
Image via Shutterstiock

Cannabis

Psychedelics

Health Care

Exclusives

Interview

ENVB

EXCLUSIVE: Non-Hallucinogenic Psychedelic Compounds Show Promise For Treating Addiction And ADHD

PRCT

PROCEPT BioRobotics Sees Q1 Revenue $65.5M Vs $66.1M Est

Vtex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTEX#NYSE">VTEX</a>) sees FY2025 sales of $235.000 million-$241.000 million vs $271.21 million analyst estimate.

VTEX

Vtex Sees FY2025 Sales $235.000M-$241.000M vs $271.21M Est

Vtex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTEX#NYSE">VTEX</a>) sees Q1 sales of $51.000 million-$52.000 million vs $57.87 million analyst estimate.

Vtex Sees Q1 Sales $51.000M-$52.000M vs $57.87M Est

First Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) reported quarterly earnings of $3.65 per share which missed the analyst consensus estimate of $4.71 by 22.51 percent. This is a 12.31 percent increase over earnings of $3.25 per share from the same period last year. The company reported quarterly sales of $1.514 billion which beat the analyst consensus estimate of $1.466 billion by 3.25 percent. This is a 30.63 percent increase over sales of $1.159 billion the same period last year.

First Solar Q4 2024 GAAP EPS $3.65 Misses $4.71 Estimate, Sales $1.514B Beat $1.466B Estimate

Workday (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NASDAQ">WDAY</a>) reported quarterly earnings of $1.92 per share which beat the analyst consensus estimate of $1.78 by 7.87 percent. This is a 22.29 percent increase over earnings of $1.57 per share from the same period last year. The company reported quarterly sales of $2.21 billion which beat the analyst consensus estimate of $2.18 billion by 1.28 percent. This is a 15.04 percent increase over sales of $1.92 billion the same period last year.

WDAY

Workday Q4 2025 Adj EPS $1.92 Beats $1.78 Estimate, Sales $2.21B Beat $2.18B Estimate

Axon Enterprise (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>) reported quarterly earnings of $2.08 per share which beat the analyst consensus estimate of $1.40 by 48.57 percent. This is a 85.71 percent increase over earnings of $1.12 per share from the same period last year. The company reported quarterly sales of $575.000 million which beat the analyst consensus estimate of $566.086 million by 1.57 percent. This is a 33.06 percent increase over sales of $432.142 million the same period last year.

Comments

Femto Technologies

Femto Technologies (FMTO) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL